|Titre :||Psychoactive substances, alcohol and tobacco consumption in HIV-infected outpatients (2018)|
|Auteurs :||J. M. JACQUET ; H. PEYRIÈRE ; A. MAKINSON ; M. PERIES ; N. NAGOT ; H. DONNADIEU-RIGOLE ; J. REYNES ; MesConsos Study group|
|Type de document :||Article : Périodique|
|Dans :||AIDS (Vol.32, n°9, June 1, 2018)|
|Article en page(s) :||1165-1171|
|Discipline :||MAL (Maladies infectieuses / Infectious diseases)|
Thésaurus mots-clésCHEMSEX ; VIH ; PSYCHOTROPES ; PREVALENCE ; ALCOOL ; TABAC ; ETUDE TRANSVERSALE ; SEROPOSITIVITE ; HSH
Objectives: To assess the alcohol consumption, tobacco addiction and psychoactive substance use (PSU) of people living with HIV (PLHIV).
Design: Cross-sectional study in an HIV outpatient unit.
Methods: Autoquestionnaire systematically proposed to all patients during their usual clinical care visit during a 6-months period, for alcohol (AUDIT test), tobacco (Short Fagerstrom Test) and PSU (ASSIST V3.0 test).
Results: Of 1334 distributed questionnaires, 1018 PLHIV responded: 76.8% were men [528 patients were MSM), and the median age was 49 years (interquartile range: 42-46). A prevalence of excessive alcohol drinking was found in 22% [95% confidence interval (CI) 19.5-24.7%] and 44.6% (CI 41.5-47.7%) were current smokers, with high dependence in 29.1% (CI 24.9-33.7%). The prevalence of PSU was 37.8% (CI 34.8-41%) in the past 3 months: cannabis 27.7%, poppers 16.4%, cocaine 8.9%, psychotropic medications 7.1%, gamma-hydroxybutyrate/gamma-butyrolactone (GHB/GBL) 4.7%, stimulants 3.1%, synthetic cathinones 2.7%, hallucinogens 1.5%. In the past 3 months, PSU was more prevalent in MSM than in non-MSM patients (46 versus 30%, P Conclusion: Given the high prevalence of PSU and other addictions (alcohol and smoking) among PLHIV, and particularly among MSM, a systematic screening of PSU and other addictions should be part of routine clinical care.
|Domaine :||Alcool / Alcohol ; Autres substances / Other substances ; Drogues illicites / Illicit drugs ; Tabac / Tobacco|
|Refs biblio. :||32|
|Affiliation :||Département de Pharmacologie Médicale et Toxicologie, Hôpital Lapeyronie, Montpellier, France|